logo-altasciences

EN - Main navigation

  • Proactive Drug Development
  • Solutions
  • Compare Us
  • Facilities
  • About Us
  • Resource Center
  • Careers
  • News & Events
  • Contact Us
  • Participate in a study
Français
  • Home
  • Clinical Services
  • Current: QT ASSESSMENT

QT ASSESSMENT

Share this page

We work with you to determine the ideal approach for measuring the QT prolongation effect of your new compound or formulation by partnering with core ECG labs for the data collection and analysis.

Some sponsors choose to add early cardiac safety assessment to their first-in-human studies, while others wait for later development and perform a Thorough QT prolongation study. Regardless of your approach, Altasciences can help you with the design. We have conducted 11 studies involving cardiac Intense/concentration QT/TQT (IQT/TQT) since 2016.

The design and conduct of studies focused on ECG measurement revolve around reducing variability in the measures, as this allows the studies to be conducted with smaller sample sizes. We consider the impact of clinical events like blood draws, and also limit other stimuli. We ensure that when the ECGs are taken, there are no events that affect heart rate.

Consult our Cardiac Assessment Fact Sheet

PARTICIPANTS

  • Healthy Normal Volunteers
11

STUDIES WITH IQT/TQT
ASSESSMENTS SINCE
2016

>28

STUDIES THAT INVOLVED
IQT/TQT ASSESSMENTS

Awarded

MULTI-YEAR, MULTI-
MILLION $
CONTRACTS WITH
NIH/NIDA AND FDA

RELATED RESEARCH

The Altascientist Issue No. 9 — Cardiac Safety Assessment in Clinical Trials_0.png

Related Research

The Altascientist Issue No. 9 — Cardiac Safety Assessment in Clinical Trials
FIH studies

Related Research

First-In-Human Trials (FIH)

THERAPEUTIC AREAS

Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.

 

Learn More

Sign up for exclusive content

Join our list of 10,000+ VIP members and have access to our exclusive content.

Stay connected

  • linkedin
  • youtube

Footer

    • Solutions

      • Preclinical Services
      • Clinical Services
      • Manufacturing and Analytical Services
      • Bioanalytical Services
      • Research Support Services
      • Development Programs
    • News & Events

      • Altasciences Events
      • Press Releases
      • Altasciences in the News
      • Press Kit
    • Resource Center

      • The Altascientist
      • Webinars/Podcasts
      • Newsletters
      • Scientific Publications
      • Blog
      • Videos
    • Study Types

      • Preclinical
      • Lead Optimization
      • Pharmacology
      • Pharmacokinetics/​Pharmacodynamics
      • Acute Toxicology
      • Dose Range Finding​/​Maximum Tolerated Dose
      • Repeated Dose Toxicity
      • Safety Pharmacology
      • Sub-Chronic/Chronic, Repeated Dose Toxicity
      • Clinical
      • First in Human
      • Proof of Concept
      • Bioavailability/Bioequivalence
      • Pharmacokinetics in Special Populations
      • Human Abuse Potential
      • Driving Simulation
      • Drug-Drug Interaction
      • QT Assessment
      • Renal and Hepatic Impaired
      • Imaging
      • Biologics​/​Biosimilars
    • Therapeutic Areas

      • Cardiology
      • Dermatology
      • Gastroenterology
      • Hematology
      • Immunology
      • Infectious Diseases
      • Metabolism and Endocrinology
      • Neurology
      • Oncology
      • Ophthalmology
      • Orthopedics
      • Psychiatry
      • Respirology
      • Rheumatology
      • Substance Abuse
      • Urology
      • Women’s Health
    • About us

      • History
      • Our Origins
      • Awards
      • Testimonials
    • Careers

    • Contact Us

    • Locations

    • Stay connected

      • Facebook
      • Youtube

2025 © Altasciences. All Rights Reserved.

Cookie Policy | Privacy Policy

Have a question?

I'd be happy to help.

Captcha is required.